Mogamulizumab-kpkc
Mogamulizumab-kpkc
Mogamulizumab-kpkc (pronounced mo-ga-mu-li-zu-mab-kpkc) is a monoclonal antibody designed for the treatment of cancer. It is also known by its brand name Poteligeo.
Etymology
The name Mogamulizumab-kpkc is derived from its structure and function. The suffix "-mab" is used for monoclonal antibodies, "-zu" indicates humanized antibody, "-li" signifies the drug's immunological target, and "-kpkc" is a unique identifier.
Usage
Mogamulizumab-kpkc is used for the treatment of Mycosis Fungoides and Sézary Syndrome, two types of cutaneous T-cell lymphoma (CTCL) that affect the skin. It is specifically used in patients who have received at least one prior systemic therapy.
Mechanism of Action
Mogamulizumab-kpkc works by binding to a protein called CCR4 found on some cancer cells. This binding triggers the immune system to destroy the cancer cells.
Side Effects
Common side effects of Mogamulizumab-kpkc include rash, infusion reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection. Serious side effects may include skin problems, infections, and lung problems.
Related Terms
External links
- Medical encyclopedia article on Mogamulizumab-kpkc
- Wikipedia's article - Mogamulizumab-kpkc
This MedicineGPT article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski